Right.
I hope Merck is giving Berger information about what and when and specific timelines etc., and not leaving him out of the loop, so to speak. Basically, I hope Berger isn't going to use the "it's in Merck's hands now..." speak going forward.
There's a couple other biotechs I own that have partnerships with Merck KaAG as well as Genentech, and every conference call, the CEO of the smaller company sounds like a fool that doesn't have any idea what is going on with the development of the compound because, apparently, the larger entity is not giving them anything.
